Libramed Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 24-10-2024
- Paid Up Capital ₹ 0.50 M
as on 24-10-2024
- Company Age 5 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.61 M
as on 24-10-2024
- Revenue 35.83%
(FY 2023)
- Profit 35.12%
(FY 2023)
- Ebitda 47.65%
(FY 2023)
- Net Worth 58.00%
(FY 2023)
- Total Assets 132.69%
(FY 2023)
About Libramed Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹7.61 M.
Vijayalakshmi, Naresh Gundluru, Bharath Gajula, and Four other members serve as directors at the Company.
- CIN/LLPIN
U52599TG2019PTC132443
- Company No.
132443
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 May 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Libramed Pharmaceuticals?
Board Members(7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vijayalakshmi  | Director | 21-Oct-2022 | Current |
| Naresh Gundluru | Additional Director | 20-Jul-2022 | Current |
| Bharath Gajula | Director | 21-Oct-2022 | Current |
| Latha Bura | Director | 21-Oct-2022 | Current |
| Pannala Reddy | Director | 26-Jul-2019 | Current |
| Mahendhar Punnam | Director | 01-May-2019 | Current |
Financial Performance of Libramed Pharmaceuticals.
Libramed Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 35.83% increase. The company also saw a substantial improvement in profitability, with a 35.12% increase in profit. The company's net worth Soared by an impressive increase of 58%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Libramed Pharmaceuticals?
In 2023, Libramed Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Jaya Vaaraahi Hospitals Private LimitedActive 1 year 5 months
Vijayalakshmi and Naresh Gundluru are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 28 Dec 2023 | ₹7.61 M | Open |
How Many Employees Work at Libramed Pharmaceuticals?
Libramed Pharmaceuticals has a workforce of 27 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Libramed Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Libramed Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
